These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6092738)

  • 41. Comparative efficacy of cefoperazone, cefoperazone plus sulbactam, ciprofloxacin, clindamycin, metronidazole, and penicillin G against anaerobic bacteria in an animal model.
    Moody JA; Fasching CE; Sinn LM; Gerding DN; Peterson LR
    J Lab Clin Med; 1990 Feb; 115(2):190-5. PubMed ID: 1967626
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Susceptibility of clinical isolates to aztreonam].
    Asari S; Horikawa M; Tsukamoto H; Kouda K; Hayashi C; Miyai K
    Jpn J Antibiot; 1987 Jul; 40(7):1317-31. PubMed ID: 3479624
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Timed bacteriostatic and bactericidal activities of latamoxef against clinical strains of gram-negative bacteria].
    Masuda G; Negishi M; Young C; Mukaiyama T; Hanai N; Uchikawa S; Thoma T; Yamazaki E
    Jpn J Antibiot; 1983 Jan; 36(1):16-21. PubMed ID: 6221128
    [No Abstract]   [Full Text] [Related]  

  • 44. [Experimental and clinical evaluation of T-1982 (cefbuperazone) in the field of obstetrics and gynecology].
    Ninomiya K; Makino S; Hasegawa Y; Yoshimoto T
    Jpn J Antibiot; 1983 May; 36(5):986-93. PubMed ID: 6352989
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anaerobic susceptibility testing. Slight differences in inoculum size can make a difference in minimum inhibitory concentrations.
    Aldridge KE; Schiro DD
    Diagn Microbiol Infect Dis; 1994 Mar; 18(3):191-5. PubMed ID: 7924212
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The in vitro and in vivo activity of taurolin against anaerobic pathogenic organisms.
    Browne MK; Leslie GB; Pfirrman RW; Brodhage H
    Surg Gynecol Obstet; 1977 Dec; 145(6):842-6. PubMed ID: 201040
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Susceptibility of strict anaerobic bacteria to antibiotics in France: a multicenter study].
    Grollier G; Mory F; Quentin C; Girard-Pipau F; Tigaud S; Sedallian A; Dubreuil L
    Pathol Biol (Paris); 1994 May; 42(5):498-504. PubMed ID: 7824321
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Bacteriological study of cefminox in the field of obstetrics and gynecology].
    Ninomiya K; Ohbayashi F; Hasegawa Y; Yoshimoto T
    Jpn J Antibiot; 1985 May; 38(5):1236-40. PubMed ID: 3930791
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro and in vivo antibacterial activity of T-1982, a new semisynthetic cephamycin antibiotic.
    Tai M; Fukuoka Y; Yotsuji A; Kumano K; Takahata M; Mikami H; Yasuda T; Saikawa I; Mitsuhashi S
    Antimicrob Agents Chemother; 1982 Nov; 22(5):728-34. PubMed ID: 6983861
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In-vitro activity of ceftizoxime against anaerobic bacteria and comparison with other cephalosporins.
    Chow AW; Finegold SM
    J Antimicrob Chemother; 1982 Nov; 10 Suppl C():45-50. PubMed ID: 6296028
    [No Abstract]   [Full Text] [Related]  

  • 51. Comparative serum bactericidal activity against test anaerobes in volunteers receiving imipenem, clindamycin, latamoxef and metronidazole.
    Van der Auwera P; Van Laethem Y; Defresne N; Husson M; Klastersky J
    J Antimicrob Chemother; 1987 Feb; 19(2):205-10. PubMed ID: 3471750
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of agar dilution, microdilution, and disk elution methods for measuring the synergy of cefotaxime and its metabolite against anaerobes.
    Smith JA; Henry D; Ngui-Yen J; Castell A; Coderre S
    J Clin Microbiol; 1986 Jun; 23(6):1104-8. PubMed ID: 2872231
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic effect of cefotetan in an experimental local infection with facultative and obligate anaerobes in granuloma pouches in rats.
    Saito M; Saito T; Yano K; Shibata K; Nishino T; Tanino T
    J Antimicrob Chemother; 1984 Feb; 13(2):133-42. PubMed ID: 6368517
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Timed bacteriostatic and bactericidal activities of cefmetazole against selected gram-negative bacteria].
    Masuda G; Young C; Negishi M; Watanabe T; Yamazaki E; Motegi K
    Jpn J Antibiot; 1982 Sep; 35(9):2288-92. PubMed ID: 6754988
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic efficacy of a new cephamycin, MT-141, in compromised mice.
    Kawaharajo K; Shitoh K; Niizeki M; Murata S; Sekizawa Y
    J Antibiot (Tokyo); 1984 Dec; 37(12):1703-11. PubMed ID: 6441793
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activity of ceftizoxime and comparative compounds against Bacteroides fragilis in a mouse model of anaerobic infection.
    Grappel SF; Phillips L; Actor P
    J Antibiot (Tokyo); 1984 Apr; 37(4):384-8. PubMed ID: 6327593
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The synergistic effect of cefotaxime and desacetylcefotaxime against clinical isolates of anaerobic bacteria.
    Devlin HR; Boskovski L
    Drugs; 1988; 35 Suppl 2():45-50. PubMed ID: 3396488
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro activity of flomoxef in comparison to other cephalosporins.
    Simon C; Simon M; Plieth C
    Infection; 1988; 16(2):131-4. PubMed ID: 3372024
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Activity of endodontic antibacterial agents against selected anaerobic bacteria.
    Ferreira CM; da Silva Rosa OP; Torres SA; Ferreira FB; Bernardinelli N
    Braz Dent J; 2002; 13(2):118-22. PubMed ID: 12238802
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cefoxitin and cephamycins: microbiological studies.
    Stapley EO; Birnbaum J; Miller AK; Wallick H; Hendlin D; Woodruff HB
    Rev Infect Dis; 1979; 1(1):73-89. PubMed ID: 400941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.